Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($14.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37), Yahoo Finance reports. Avalo Therapeutics had a negative net margin of 1,639.50% and a negative return on equity of 1,439.87%.
Avalo Therapeutics Stock Down 0.9 %
NASDAQ:AVTX opened at $9.82 on Wednesday. Avalo Therapeutics has a 1-year low of $3.95 and a 1-year high of $71.04. The company has a 50-day moving average of $11.78 and a 200 day moving average of $10.29.
Analyst Upgrades and Downgrades
Separately, Oppenheimer raised Avalo Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, April 16th.
Avalo Therapeutics Company Profile
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Featured Articles
- Five stocks we like better than Avalo Therapeutics
- Compound Interest and Why It Matters When Investing
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- Short Selling: How to Short a Stock
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
